Clinical Study

Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Table 3

Grade 3-4 toxicity summary statistics for all 33 treated patients.

Grade 3-4 toxicity 𝑁 EventsPoint estimate95% confidence interval

Anemia331339%25%56%
Neutropenia331030%17%47%
Hyponatremia331030%17%47%
Dehydration3339%3%24%
Fatigue3339%3%24%
Dyspnea3339%3%24%
Pneumonia3339%3%24%
Thrombocytopenia3326%2%20%
Febrile neutropenia3313%1%15%
Tachycardia3313%1%15%
Syncope3313%1%15%
Fluid retention3313%1%15%
Mucositis3313%1%15%
Hyperglycemia3313%1%15%
Constipation3313%1%15%
Anorexia3313%1%15%
Vomiting3313%1%15%
Other nonhematologic toxicity3313%1%15%